COPY OF INSTRUCTION 271I DATED OCTOBER 1985 SHOWING DETAILS OF IN VIVO TUMOR TESTING

MODEL	TUMOR	HOST PROPAGATION	HOST TESTING	APPROX TUMOR TRANSFER DAY	PROPAGATION INOCULUM SITE	PROPAGATION INOCULUM TISSUE (3)(8)	PROPAGATION INOCULUM LEVEL PER MOUSE	TEST INOCULUM SITE	TEST INOCULUM TISSUE (3)(8)	TEST INOCULUM LEVEL PER MOUSE	DOUBLING TIME (DAYS)(9)	APPROX LE EQUIV	MICE PER TEST	DRUG ROUTE & SCHEDULE	CONTROL SECOND WEIGH DAY	CONTROL TEST TOXICITY DAY	CONTROL EARLY DEATH DAY	CONTROL NO TAKE DAY	CONTROL FINAL EVALUATION DAY (FED)	CONTROL PARAMETER (RELATIVE TO CONTROL)	CONTROL ACCEPTABLE CONTROL RANGE	POSITIVE CONTROL COMPOUND NSC	POSITIVE CONTROL COMPOUND ROUTE & TREATMENT	POSITIVE CONTROL COMPOUND DOSE (MG/KG INJECTION	TEST T/C% T/C %	TEST T/C% TOXICITY	TEST T/C% GRAMS: NEGATIVE (4) BODY WEIGHT CHANGE DIFFERENCE	TEST T/C% ACTIVE CRITERION	TEST T/C% DN2 CRITERION IF CONFIRMED	MODEL
3B131	B1 - B16 MELANOMA	C57BL/6	B6C3F1	12	SC	FRAGMENT 1:10 BREI	25 MG 0.5 ML	IP	1:10 BREI	0.5 ML	1.3-2.8	2	1O	IP QD D1-9	5	5	12	30	60	MEDIAN SURVIVAL TIME	15-22 DAYS	119875	IP QD 1-9	2 & 1	≥ 135	≤ 85	≥ 4	≥125	≥ 150 (15)	3B131
3B132	B1 - B16 MELANOMA	C57BL/6	B6D2F1	12	SC	FRAGMENT 1:10 BREI	25 MG 0.5 ML	SC	FRAGMENT 1:10 BREI	25 MG 0.5 ML	0.8-1.6 NE	2	10	IP QD D1-9	5	5	13	46	60	MEDIAN SURVIVAL TIME	21-31 DAYS	19893 26271 125066	IP QD 1-9 IP QD 1-9 IP QD 1-9	20 50 12,6 & 3	≥135 ≥135 ≥135	≤ 85	≥4	≥140	≥ 150	3B132
3B137	B1 - B16 MELANOMA	C57BL/6	B6D2F1	12	SC	FRAGMENT 1:10 BREI	25 MG 0.5 ML	IC	1X10(5) CELLS	0.05 ML	1.4	NE	10	IP QD D1-9	5	5	7	24	30/60	MEDIAN SURVIVAL TIME	11-18 DAYS	409962	IP SINGLE D1	32 & 24	≥140	≤85	≥ 4	≥125	≥ 150	3B137
3CDJ2	CD - CD8F1 MAMMARY ADENOCARCINOMA	CD8F1 FEMALE	CD8F1	NA		SPONTANEOUS IN CD8F1 FEMALES		SC	1:20 BREI	0.3 ML	1.6-4.1 (10)	3	10	IP SINGLE ON STAGING DAY	FED	FED	FED	FED	7 DAYS POST STAGING DAY	MEDIAN TUMOR WEIGHT CHANGE	400-2000 MG	26271	IP SINGLE ON STAGING DAY (2)	250	< 20	NA	≥ 7	≤ 20	< 0	3CDJ2
3C872	C8 - COLON 38 CARCINOMA	C57BL/6	B6C3F1 OR B6D2F1	20	SC	FRAGMENT (13 GAUGE TROCAR)	70 MG	SC	FRAGMENT	70 MG	0.7 - 3.2	3	10	IP Q7D X 2 START DAY 2	20	20	20	20	20	MEDIAN TUMOR WEIGHT INHIBITION	400-2000 MG	19893	IP Q7DX2 START DAY 2	70	≤42	NA	NA	≤ 42	≤ 10	3C872
3EM37 OR 3EP37	EM OR EP EPENDYMO-BLASTOMA	C57BL/6	B6C3F1 OR C57BL/6	14	SC	FRAGMENT 2X2X8 MM		IC	1X10 (5) CELLS FRAGMENT	0.05 ML 1X1X1 MM	NE	2.75	10	IP QD 1-5	5	5	10	40	60	MEDIAN SURVIVAL TIME	14 - 30 DAYS	409962	IP QD 1-5	8,4 & 2	≥135	≤85	≥ 4	≥ 125	≥ 150	3EM37 OR 3EP37
3LE31	LE -L1210 LEUKEMIA	DBA/2	CD2F1 OR B6D2F1	7	IP	1X10 (5) CELLS	0.1 ML	IP	1 X 10 (5) CELLS	0.1 ML	0.24-0.34	1	6	IP QD 1-5	5	5	6	18	30/60	MEDIAN SURVIVAL TIME	7.5-10.5 DAYS	19893	IP QD 1-5	20	≥ 135	≤85	≥ 4	≥ 125	≥ 150 (15)	3LE31
3LE32	LE -L1210 LEUKEMIA	DBA/2	CD2F1	7	IP	1X10 (5) CELLS	0.1 ML	SC	1 X 10 (5) CELLS	0.1 ML	0.4-0.6	2	10	IP QD 1-9	5	5	6	18	30	MEDIAN SURVIVAL TIME	9-12 DAYS	740	IP QD 1-9	2 & 1	≥ 135	≤85	≥ 4	≥ 125	≥ 150	3LE32
3LE37	LE -L1210 LEUKEMIA	DBA/2	CD2F1 OR B6D2F1	7	IP	1X10 (5) CELLS	0.1 ML	IC	1 X 10 (4) CELLS	0.05 ML	0.4	2.75	6-10	IP QD 1-9	5	5	6	21	30/60	MEDIAN SURVIVAL TIME	8-11 DAYS	409962	IP SINGLE-D1	32 & 24	≥ 135	≤85	≥ 4	≥125	≥150	3LE37
3LO31	LO - LOX AMELANOTIC MELANOMA	NCr-nu	NCr-nu	7-11	IP	1X10(7) CELLS	0.1 ML	IP	1 X 10 (6) CELLS	0.1 ML	NE	3	6	IP Q4DX3 START DAY 1	10	10	NE	NE	60	MEDIAN SURVIVAL TIME								≥ 140	≥ 200	3LO31
3MBG5	MB-MX-1 MAMMARY CARCINOMA XENOGRAFT	Cr:NIH(S)-nu OR NcR-nu	Cr:NIH(S)-nu OR NCr-NU	14	SC	FRAGMENT 2X2X2 MM		SRC	FRAGMENT	1X1X1 MM	2.6	7	6	IP Q4DX3 START DAY 1	11	11	11	11	11	MEDIAN TUMOR WEIGHT CHANGE	≥ 20% TUMOR GROWTH	NA	NA	NA	NA	NA	≥ 6	≤ 20	≤ 10	3MBG5
3MBH2	MB-MX-1 MAMMARY CARCINOMA XENOGRAFT	Cr:NIH(S)-nu OR NCr-nu	Cr:NIH(S)-nu OR NCr-nu	28	SC	FRAGMENT	25 MG	SC	FRAGMENT	14 MG	3.9 (11)	5	6-10	IP Q4DX3 (2)	VAR	VAR	VAR	NA	VARIABLE	MEDIAN TUMOR WEIGHT CHANGE	NE	7365				NE	NE	≤ 20	≤ 10	3MBH2
3M531	M5-M5076 ASCITES SARCOMA BREI	C57BL/6 FEMALE	B6C3F1	14-19 21	IP SC	1X10(6) CELLS 1:10 BREI	0.1 ML 0.5 ML	IP IP	1X10(6) CELLS 1:10 BREI	0.1 ML 0.5 ML	1.0-2.0 (12) (APPROX. 2.6 MG)	3	10	IP Q4DX4 START DAY DAY 1	14	14	14	40	60	MEDIAN SURVIVAL TIME	20-28 DAYS 20-34 DAYS	26271	IP Q4DX4 START DAY 1	160,80,40	≥ 150	≤ 85	≥ 4	≥ 125 ≥ 135	≥ 150 ≥ 165	3M531
3M532	M5-M5076 ASCITIES SARCOMA FRAG.	C57BL/6 FEMALE	B6C3F1	14-19 21	IP SC	1X10(6) CELLS FRAGMENT 2-3 MM(3)	0.1 ML	SC SC	5X10(6) CELLS FRAGMENT	0.5 ML 2X2X2 MM	0.9-2.0 2.1 (APPX. 8 MG)	3	10 10	IP Q4D START DAY 1 IP Q2DX11 START DAY 1	18 5	17 5	18 18	48 48	75 60	MEDIAN SURVIVAL TIME	29-40 DAYS 30-37 DAYS	409962 95441	IP Q4DX4 START DAY 1 IP Q2DX11 START DAY 1	12 & 6 10 & 5	≥ 150 ≥ 135	≤ 85 ≤ 85	NE NE	≥ 125 ≥125	≥ 150 ≥ 150	3M532
3M572	M5-M5076 SARCOMA (ASCITIC)	C57BL/6 FEMALE	B6C3F1	14-19	IP	1X10(6) CELLS	0.1 ML	SC	5X10(6) CELLS	0.5 ML	NE	3	10	IP Q4DX4 START DAY 1	21	21	21	21	21	MEDIAN TUMOR WEIGHT INHIBITION	1000-4000 MG	409962	IP Q4DX4 START DAY 1	12 & 6	≤ 10	NA	NE	≤ 30	≤ 10	3M572
3PA31	PA-P388 LEUKEMIA ADRIAMYCIN RESISTANT	DBA/2	CD2F1	7	IP	1X10(6) CELLS	0.1 ML	IP	1X10(6) CELLS	0.1 ML	NE	1	10	SAME AS SENSITIVE P388	5	5	7	18	30	MEDIAN SURVIVAL TIME	9-14 DAYS	19893	IP QD D1-5	25 & 15	≥ 135	≤ 85	≥ 4	NA	NA	3PA31
3PS31	PS-P388 LEUKEMIA SYNTHETIC NATURAL PRODUCT	DBA/2	CD2F1	7	IP	1X10(6) CELLS	0.1 ML	IP	1X10(6)	0.1 ML	0.39-0.52	1	6 (SYN) 4 (NP FRACTION EXCEPT 6 FOR K FRACTION)	IP QD D1-5 IP QD D1-9	5	5	7	18	30	MEDIAN SURVIVAL TIME	9-13 DAYS	19893	IP QD D1-5 IP QD D1-9	20	≥ 135	≤ 85	≥ 4	≥ 127(13) (SYN) ≥ 130 (NP)	≥ 175	3PS31
3PS32	PS-P388 LEUKEMIA	DBA/2	CD2F1	7	IP	1X10(6) CELLS	0.1 ML	SC	1X10(6) CELLS	0.1 ML	NE	2	10	IP QD D1-5	8	8	9	22	30	MEDIAN SURVIVAL TIME	13-16 DAYS	8806	IP QD D1-5	4 & 2	≥ 150	≤ 85	NE	≥ 125	≥ 150	3PS32
3PS37	PS-P388 LEUKEMIA	DBA/2	CD2F1	7	IP	1X10(6) CELLS	0.1 ML	IC	1X10(5) CELLS	0.05 ML	0.6	2.75	10	IP QD D1-9	5	5	7	22	30/60	MEDIAN SURVIVAL TIME	9-13 DAYS	409962	IP SINGLE DAY 1	32 & 24	≥ 135	≤ 85	≥ 4	≥ 125	≥ 175	3PS37
MODEL	TUMOR	PROPAGATION HOST	TESTING	APPROX TUMOR TRANSFER DAY	SITE	TISSUE (3)	LEVEL PER MOUSE	SITE	TISSUE	LEVEL PER MOUSE	DOUBLING TIME (DAYS)(9)	APPROX LE EQUIV	MICE PER TEST	DRUG ROUTE AND SCHEDULE	SECOND WEIGH DAY	TEST TOXICITY DAY	EARLY DEATH DAY	NO TAKE DAY	FINAL EVALUATION DAY (FED)	PARAMETER (RELATIVE TO CONTROL)	ACCEPTABLE CONTROL RANAGE	NSC	ROUTE & TREATMENT	DOSE (MG/KG/ INJECTION)	T/C %	TOXICITY	GRAMS:NEGATIVE (4) BODY WEIGHT CHANGE DIFFERENCE (T-C)	ACTIVE CRITERION	DN2 CRITERION (IF CONFIRMED)	MODEL

CONTROL

(1) CODES FOR DATA MAY BE FOUND IN INSTRUCTION 14.
(2) TREATMENT STARTS WHEN TUMORS REACH WEIGHT OF 100 MG TO 700 MG.
(3) ALL CELL COUNTS ARE TOTAL INTACT CELLS.
(4) ANIMAL-WEIGHT-CHANGE DIFFERENCE CUTOFF:EXCESS LOSS INDICATES POSSIBLE TOXICITY;OR POSSIBLE FALSE MC1 LEVEL ACTIVITY IN A TUMOR-WEIGHT-INHIBITION TEST.
(5) THE INFORMTION ON THE MOST RECENT REVISION OF THIS CHART TAKES PRECEDENCE OVER PREVIOUS INSTRUCTIONS.
(6) THE NEXT REVISION OF THIS CHART IS IN PREPARATION: SEND YOUR SUGGESTIONS TO YOUR NCI PROJECT OFFICER.
(7) SRC = SUB-RENAL-CAPSULE.
(8) BREI DILUTION IS GRAMS OF TUMOR TISSUE IN MILLILITERS OF FINAL BREI (E.G., IN A 1:10 BREI, 10 ML. OF BREI INCLUDES 1 GRAM OF TUMOR TISSUE).
(9) APPROXIMATE DOUBLING TIME (DAYS) OF TUMOR AT IMPLANT SIZE ASSUMING 100% VIABILITY.
(10) APPROXIMATE DOUBLING TIME RANGE FOR TMORS BETWEEN 100MG AND 700 MG ON STAGING DAY.
(11) APPROXIMATE DOUBLING TIME FOR A 100 MG TUMOR, WHICH IS THE APPROXIMATE TUMOR SIZE AT BEGINNING OF TRETMENT.
(12) RANGE OF 3M531 (BREI) DOUBLING TIMES 0.7 - 3.4 DAYS.
(13) 3PS31 T/C MUST BE ≥ 127 TO RETEST - CONFIRMED IF 2ND TEST ≥ 120.
(14) POSITIVE CONTROL TESTING DONE BY TUMOR BANK.
(15) MUST DEMONSTRATE ACTIVITY AT TWO DOSE LEVELS IN 2/3 INTERVAL DOSE RESPONSE.

APPROX - APPROXIMATE
NA - NOT APPLICABLE
NE - NOT ESTABLISHED
VAR - VARIABLE